Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AIDS vaccine 2001.

F Gotch1

  • 1Department of Immunology, Division of Investigative Science, Faculty of Medicine, Imperial College of Science, Technology and Medicine, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK. f.gotch@ic.ac.uk

Idrugs : the Investigational Drugs Journal
|June 16, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dysregulated immunophenotypic attributes of plasmacytoid but not myeloid dendritic cells in HIV-1 infected individuals in the absence of highly active anti-retroviral therapy.

Clinical and experimental immunology·2012
Same author

Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial.

Vaccine·2011
Same author

Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals.

Clinical and experimental immunology·2009
Same author

Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.

Vaccine·2008
Same author

A mathematical model comparing solute kinetics in low- and high-BMI hemodialysis patients.

The International journal of artificial organs·2007
Same author

A kinetic model of calcium mass balance during dialysis therapy.

Blood purification·2006
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

The urgent need for an effective human immunodeficiency virus (HIV) vaccine is highlighted by millions of annual infections, particularly in developing nations. Exploring novel vaccine strategies is crucial for reducing HIV transmission and disease, even without full sterilizing immunity.

Area of Science:

  • Immunology
  • Vaccinology
  • Public Health

Background:

  • 5.4 million new human immunodeficiency virus (HIV) infections occur annually, with 10% in children and 50% in females.
  • Over 90% of infections are in developing countries lacking widespread access to antiretroviral therapy.
  • The high global burden necessitates the development of a prophylactic HIV vaccine.

Purpose of the Study:

  • To review novel candidate vaccines and strategies discussed at 'AIDS Vaccine 2001'.
  • To emphasize the importance of exploring diverse vaccine approaches and comparing induced immune responses.
  • To assess the potential impact of vaccines, even those not providing sterilizing immunity, on HIV pathogenesis and transmission.

Main Methods:

  • Review of presentations and discussions from the 'AIDS Vaccine 2001' conference.

Related Experiment Videos

  • Focus on slide sessions detailing new vaccine candidates and strategies.
  • Analysis of the importance of comparative studies on vaccine-induced responses.

    • Main Results:

    • Multiple novel vaccine strategies and candidates were presented.
    • The critical need for exploring a wide range of approaches was underscored.
    • The potential for partially effective vaccines to significantly impact HIV disease and transmission was discussed.

    Conclusions:

    • A prophylactic human immunodeficiency virus (HIV) vaccine is a compelling necessity due to the global epidemic.
    • Exploring diverse and novel vaccine strategies is essential for progress.
    • Even partially effective vaccines could substantially reduce HIV disease progression and transmission, offering significant public health benefits.